Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial

BACKGROUND: Cardiovascular (CV) disease (CVD) is a well-recognized complication of type 2 diabetes mellitus (T2DM) and there is a clinical need for glucose-lowering therapies that do not further increase CV risk in this population. Although sulfonylureas (SUs) may be used as second-line therapy for...

Descripción completa

Detalles Bibliográficos
Autores principales: Santamarina, Marile, Carlson, Curt J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419798/
https://www.ncbi.nlm.nih.gov/pubmed/30876392
http://dx.doi.org/10.1186/s12872-019-1036-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419798/
https://www.ncbi.nlm.nih.gov/pubmed/30876392
http://dx.doi.org/10.1186/s12872-019-1036-0

Ejemplares similares